Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
License to market regenerative medical productsHLCM051
Applicable field (uses covered by this announcement)
Acute Respiratory Distress Syndrome (ARDS)Acute phase of cerebral infarctionTrauma-induced acute kidney injury (AKI)Cancer immunotherapyOphthalmologyLiver disease
Launch date24 August 2026 (license certificate issued)
Relationship between the counterparty and the company
HEALIOS K.K.4593
CounterpartyGovernor of Hyogo Prefecture
Award/certification name
License Certificate to Manufacture and Market Regenerative Medicine Products
Awarding / certifying body
Governor of Hyogo Prefecture
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | License to market regenerative medical products, HLCM051 |
| Counterparty | Governor of Hyogo Prefecture |
| Launch date | 24 August 2026 (license certificate issued) |
| Applicable area | Acute Respiratory Distress Syndrome (ARDS), Acute phase of cerebral infarction, Trauma-induced acute kidney injury (AKI), Cancer immunotherapy, Ophthalmology, Liver disease |
| Award/certification name | License Certificate to Manufacture and Market Regenerative Medicine Products |
| Awarding / certifying body | Governor of Hyogo Prefecture |
Items this document does not state (12)
Counterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company re-obtained the license, which it first obtained in April 2022, following a review of its product development plans.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.